Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors
Giorgia Anastasio, Michela Felaco, Alessia Lamolinara, Francesco del Pizzo, Elisa Cacciagrano, Carla Mottini, Margherita Mutarelli, Francesca Di Modugno, Manuela Iezzi, Luca Cardone
This paper shows that low-dose decitabine combined with olaparib enhances antitumor activity in KRAS-dependent pancreatic ductal adenocarcinoma, regardless of BRCA1/2 status.
iScience · Jan 20, 2025Peer-reviewedCancer Biology